1. Home
  2. MTH vs CRSP Comparison

MTH vs CRSP Comparison

Compare MTH & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meritage Homes Corporation

MTH

Meritage Homes Corporation

HOLD

Current Price

$61.17

Market Cap

4.1B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$47.50

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTH
CRSP
Founded
1985
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.4B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
MTH
CRSP
Price
$61.17
$47.50
Analyst Decision
Buy
Buy
Analyst Count
8
17
Target Price
$84.38
$70.29
AVG Volume (30 Days)
845.7K
1.9M
Earning Date
04-22-2026
05-05-2026
Dividend Yield
3.15%
N/A
EPS Growth
N/A
N/A
EPS
6.35
N/A
Revenue
N/A
$289,590,000.00
Revenue This Year
N/A
$1,082.59
Revenue Next Year
$9.75
$87.74
P/E Ratio
$9.61
N/A
Revenue Growth
N/A
9169.85
52 Week Low
$58.03
$30.06
52 Week High
$84.54
$78.48

Technical Indicators

Market Signals
Indicator
MTH
CRSP
Relative Strength Index (RSI) 33.20 41.17
Support Level N/A $46.78
Resistance Level $69.51 $60.63
Average True Range (ATR) 1.95 2.17
MACD -0.39 -0.66
Stochastic Oscillator 29.96 16.83

Price Performance

Historical Comparison
MTH
CRSP

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: